Company intelligence / Profile preview
StemCyte Inc.
Baldwin Park, California, United Statesstemcyte.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
StemCyte received FDA approval for REGENECYTE™, a cord blood cell therapy product for transplantation in patients with blood and immune system disorders in November 2024. The company has provided more than 2,300 cord blood units to over 350 transplant centers worldwide. They are also conducting Phase II clinical trials for long COVID syndrome and acute stroke.
- Therapeutic areas
- OncologyImmunologyHematologyNeurologyInfectious Diseases
- Modalities
- Cord blood stem cell therapyHematopoietic stem cell therapy
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
Apollo HospitalsCadila PharmaceuticalsCity of HopeTaipei Medical University HospitalTzu Chi HospitalKaiserCell Research CorporationCalifornia governmentUC Davis
Beyond the preview
Go deeper on StemCyte Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StemCyte Inc..